LLY — ELI LILLY & Co

—
NYSE · Health Care · Pharmaceuticals · CIK 59478 ·
Last close
$1183.46
Market Cap
$1.06T
52W High
$1292.65
52W Low
$711.59
ADV30
2,422,043
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 22,974,000,000 19,706,000,000 12,457,000,000 7,095,000,000 142,283,000,000 8,950,000,000 108,404,000,000
Mar 2026 19,799,000,000 16,222,000,000 9,778,000,000 7,396,000,000 116,576,000,000 5,282,000,000 85,378,000,000
Dec 2025 19,292,000,000 15,920,300,000 8,987,400,000 6,637,700,000 112,476,000,000 7,268,000,000 85,941,000,000
Sep 2025 17,600,800,000 14,592,500,000 8,386,100,000 5,582,500,000 114,935,400,000 9,791,900,000 91,084,600,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$20,480,000,000
Investing CF
$-11,535,000,000
Financing CF
$-7,063,000,000
CapEx
$-10,112,000,000
Dividends Paid
$-5,586,000,000
Buybacks
$-5,264,000,000
EPS Diluted TTM
$28.15
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$29,514,000,000
Inventory
$14,529,000,000
Receivables
$21,177,000,000
ST Investments
$121,600,000
EBIT TTM
$35,774,200,000
Pretax Income TTM
$31,125,000,000
Interest Exp TTM
$897,000,000
Analysts
27

Yahoo Snapshot (yfinance, live)

Total Revenue
$79,666,003,968
EBITDA
$41,706,999,808
Free Cash Flow
$11,065,900,032
Enterprise Value
$1,040,445,079,552
Total Cash
$8,949,999,616
Total Debt
$54,907,998,208
Shares Out
891,741,406
Trailing EPS
$29.79
Book Value
$38.00
ROE
102.3%
ROA
20.4%
Div Yield
0.62%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 65,179,000,000 29,696,000,000 20,640,000,000 112,476,000,000 85,941,000,000 26,535,000,000 16,813,000,000
Dec 2024 45,043,000,000 17,040,000,000 10,590,000,000 78,715,000,000 64,443,000,000 14,272,000,000 8,818,000,000
Dec 2023 34,124,000,000 10,325,000,000 5,240,000,000 64,006,300,000 53,142,600,000 10,771,900,000 4,240,000,000
Dec 2022 28,541,400,000 8,280,400,000 6,244,800,000 49,489,800,000 38,714,400,000 10,649,800,000 7,585,700,000

TTM Snapshot

Revenues TTM
$40,608,300,000
NetIncome TTM
$5,123,600,000
OpCashFlow TTM
$0
Assets (Latest)
$112,476,000,000
Forward EPS
$47.24

Max Pain — expiry 2026-10-02

max pain strike: $1160.00 · spot: $1189.95 · call oi: 12,658 · put oi: 14,520
Expected Move to 2026-10-02: ±$37.75 (3.17%) — implied range $1152.20 – $1227.70 · ATM straddle on $1190.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
JNJ JOHNSON & JOHNSON $653.61B $271.22 —
ABBV AbbVie Inc. $467.12B $264.34 —
MRK Merck & Co., Inc. $367.07B $148.78 —
NVS NOVARTIS AG $276.48B $145.46 —
AZN ASTRAZENECA PLC $258.35B $166.58 —

News headlines (Yahoo Finance, 1h cache)

He Will Switch Contractors to Help Build Eli Lilly’s $6.5 Billion Plant. Two W-2s Could Put $2,821 in Social Security Taxes Back in His Pocket
2026-09-28 14:32 · Yahoo
Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?
2026-09-28 13:21 · Yahoo
Eli Lilly Wavered Over the Last Month: One of Wall Street’s Biggest Banks Says 35% Gains Still to Come
2026-09-28 12:12 · Yahoo
Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs
2026-09-28 10:45 · Yahoo
Eli Lilly Just Announced Game-Changing News
2026-09-28 08:23 · Yahoo
Eli Lilly Wins FDA Approval for Weekly Insulin. Here’s What Comes Next
2026-09-28 06:32 · Yahoo
Eli Lilly and Company (LLY) is Expanding Beyond its Biggest Growth Drivers. Can it Sustain the Momentum?
2026-09-28 04:11 · Yahoo
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
2026-09-28 03:31 · Yahoo
A New Wave of Senior Patients Could Extend Lilly’s GLP-1 Growth Story
2026-09-27 20:26 · Yahoo
Lilly’s Oral GLP-1 Push Gains Momentum. Can Foundayo Become its Next Growth Engine?
2026-09-27 20:24 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.